| Sun Guizhi,Cui Minghu,Du Mengmeng,Wu Xiaorui,Zhang Lanlan,Zhang Shudong,Efficacy and safety of agomelatine in the treatment of first-episode depression: a Meta-analysis[J].SICHUAN MENTAL HEALTH,2020,33(3):257-262 |
| Efficacy and safety of agomelatine in the treatment of first-episode depression: a Meta-analysis |
DOI：10.11886/scjsws20200311001 |
| English keywords:First-episode depression Agomelatine SSRIs/SNRIs Meta-analysis |
| Fund projects:滨州医学院科研启动基金（项目基金：首发抑郁症患者头发皮质醇激素水平的相关研究，项目编号：BY2016KJ24） |
| Author Name | Affiliation | Postcode | | Sun Guizhi | Binzhou Medical University Hospital, Shandong 256600, China | 256600 | | Cui Minghu | Binzhou Medical University Hospital, Shandong 256600, China | 256600 | | Du Mengmeng | Binzhou Medical University Hospital, Shandong 256600, China | 256600 | | Wu Xiaorui | Binzhou Medical University Hospital, Shandong 256600, China | 256600 | | Zhang Lanlan | Binzhou Medical University Hospital, Shandong 256600, China | 256600 | | Zhang Shudong | Binzhou Medical University Hospital, Shandong 256600, China | 256600 |
|
| Hits: |
| Download times: |
| English abstract: |
| Objective To systematically assess the efficacy and safety of agomeltine in the treatment of first-episode depression, so as to provide references for drug treatment of depression.Methods Randomized controlled trials (RCTs) related to agomeltine in the treatment of first-episode depression published in PubMed, Web of Science, CNKI, VIP, and Wangfang were retrieved.Extracted data on the efficacy and safety of agomelatine and SSRIs/SNRIs in the treatment of first-episode depression,and the collected data were processed by RevMan 5.3 software.Results A total of 12 RCTs were included (10 in Chinese and 2 in English). Meta-analysis showed that the HAMD-17 scores of agomelatine group were statistically different from those of control group (SMD=-1.31, 95% CI: -1.55~-1.07, Z=10.77, P<0.01). High heterogeneity was found in control group (I2=83%, P<0.01), so subgroup analysis was further performed, and the results indicated that HAMD-17 scores of fluoxetine subgroup (SMD=-1.22, 95% CI: -1.66~-0.77, Z=5.30, P<0.01) and duloxetine subgroup (SMD=-0.88, 95% CI: -1.26~-0.50, Z=4.49, P<0.01) showed significant different with those of agomelatine group. The incidence of side effects were statistically different between groups (RR=0.63, 95% CI: 0.49~0.81, Z=3.73, P<0.01).Conclusion Agomelating is superior or comparable to SSRIs/SNRIs antidepressants in the treatment of first-episode depression, and has fewer side effects than SSRIs/SNRIs antidepressants. |
| View Full Text
View/Add Comment Download reader |
| Close |
|
|
|